Press release -
Athera allowed European composition of matter patents for therapeutic antibodies
Stockholm Feb 28, 2018 Athera Biotechnologies AB today announced that a composition of matter patent covering antibodies with binding to phosphorylcholine, PC has been allowed by the European Patent Office, EPO. The PC target is part of modified phospholipids and has been characterized as an active driver of vascular inflammation. The therapeutic antibodies covered by the patent are designed to target and block PC and thereby reduce inflammation.
“The EPO allowance is following the previous grant of corresponding US, Japanese and Australian patents covering both our lead candidate PC-mAb and a second candidate” says Carina Schmidt, CEO of Athera.
The clinical stage fully human antibody PC-mAb from Athera is designed to mimic the anti-inflammatory role of endogenous antibodies against PC and act to support the immune response to vascular inflammation challenges and thereby reduce the risk for complications in immunovascular diseases.
For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB
Phone: +46 (0)76 1938 190, email: c.schmidt@athera.se
Topics
- Corporate Information
Categories
- immunovascular
- vascular
- phospholipids
- inflammation
- therapeutic antibody
- patent
- läkemedel
- clinical
- cardiovascular disease
- hjärtkärlsjukdom
- athera biotechnologies
- athera
About Athera Biotechnologies AB
The mission of Athera is to address the large unmet need for anti-inflammatory therapeutics in the treatment of immunovascular disease. Athera´s focus is on PC-mAb, a clinical stage biopharmaceutical program with block-buster potential. Development of PC-mAb has been co-funded by EU FP7 in the CARDIMMUN project. Major shareholders are Industrifonden, The Foundation for Baltic and East European Studies (Östersjöstiftelsen) and Linc AB.For more information: www.athera.se
